Literature DB >> 9618523

NF-kappaB activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1alpha.

P Bhat-Nakshatri1, T R Newton, R Goulet, H Nakshatri.   

Abstract

Several angiogenic factors and extracellular matrix-degrading enzymes that promote invasion and metastasis of cancer are produced by stromal fibroblasts that surround cancer cells. The expression of genes that code for some of these proteins is regulated by the transcription factor NF-kappaB. In this report, we demonstrate that conditioned medium (CM) from estrogen receptor (ER)-negative but not ER-positive breast cancer cells induces NF-kappaB in fibroblasts. In contrast, CM from both ER-positive and ER-negative breast cancer cells induces NF-kappaB in macrophages and endothelial cells. NF-kappaB activation in fibroblasts was accompanied by induction of interleukin 6 (IL-6) and urokinase plasminogen activator (uPA), both of which promote angiogenesis and metastasis. A survey of cytokines known for their ability to induce NF-kappaB identified IL-1alpha as the factor responsible for NF-kappaB activation in fibroblasts. Analysis of primary breast carcinomas revealed the presence of IL-1alpha transcripts in majority of lymph node-positive breast cancers. These results along with the known role of IL-1alpha and IL-6 in osteoclast formation provide insight into the mechanism of metastasis and hypercalcemia in advanced breast cancers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9618523      PMCID: PMC22705          DOI: 10.1073/pnas.95.12.6971

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  51 in total

1.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas.

Authors:  P Basset; J P Bellocq; C Wolf; I Stoll; P Hutin; J M Limacher; O L Podhajcer; M P Chenard; M C Rio; P Chambon
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

2.  Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression.

Authors:  A D'Errico; S Garbisa; L A Liotta; V Castronovo; W G Stetler-Stevenson; W F Grigioni
Journal:  Mod Pathol       Date:  1991-03       Impact factor: 7.842

Review 3.  The process of malignant progression in human breast cancer.

Authors:  R Clarke; R B Dickson; N Brünner
Journal:  Ann Oncol       Date:  1990-11       Impact factor: 32.976

4.  Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function.

Authors:  C Singer; A Rasmussen; H S Smith; M E Lippman; H T Lynch; K J Cullen
Journal:  Cancer Res       Date:  1995-06-01       Impact factor: 12.701

5.  Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity.

Authors:  C Nerlov; P Rørth; F Blasi; M Johnsen
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

6.  Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice.

Authors:  J E Price; A Polyzos; R D Zhang; L M Daniels
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

7.  Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines.

Authors:  E W Thompson; S Paik; N Brünner; C L Sommers; G Zugmaier; R Clarke; T B Shima; J Torri; S Donahue; M E Lippman
Journal:  J Cell Physiol       Date:  1992-03       Impact factor: 6.384

8.  Involvement of nuclear factor-kappa B in induction of the interleukin-6 gene by leukemia inhibitory factor.

Authors:  H J Gruss; M A Brach; F Herrmann
Journal:  Blood       Date:  1992-11-15       Impact factor: 22.113

9.  Structural organization and the transcription initiation site of the human hepatocyte growth factor gene.

Authors:  K Miyazawa; A Kitamura; N Kitamura
Journal:  Biochemistry       Date:  1991-09-24       Impact factor: 3.162

10.  A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene.

Authors:  S K Hansen; C Nerlov; U Zabel; P Verde; M Johnsen; P A Baeuerle; F Blasi
Journal:  EMBO J       Date:  1992-01       Impact factor: 11.598

View more
  18 in total

1.  Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.

Authors:  Britton Trabert; Ligia Pinto; Patricia Hartge; Troy Kemp; Amanda Black; Mark E Sherman; Louise A Brinton; Ruth M Pfeiffer; Meredith S Shiels; Anil K Chaturvedi; Allan Hildesheim; Nicolas Wentzensen
Journal:  Gynecol Oncol       Date:  2014-08-23       Impact factor: 5.482

2.  Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells.

Authors:  Dinesh Vyas; Nicolas Lopez-Hisijos; Sulakshana Gandhi; M El-Dakdouki; Marc D Basson; Mary F Walsh; X Huang; Arpita K Vyas; Lakshmi S Chaturvedi
Journal:  J Nanosci Nanotechnol       Date:  2015-09

3.  Antioxidant and anti-inflammatory effects of Ruta chalepensis L. extracts on LPS-stimulated RAW 264.7 cells.

Authors:  Mohamed Kacem; Gaëlle Simon; Raphael Leschiera; Laurent Misery; Abdelfattah ElFeki; Nicolas Lebonvallet
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-10-02       Impact factor: 2.416

4.  MMB triazole analogs are potent NF-κB inhibitors and anti-cancer agents against both hematological and solid tumor cells.

Authors:  Venumadhav Janganati; Jessica Ponder; Meenakshisundaram Balasubramaniam; Poornima Bhat-Nakshatri; Eli E Bar; Harikrishna Nakshatri; Craig T Jordan; Peter A Crooks
Journal:  Eur J Med Chem       Date:  2018-08-10       Impact factor: 6.514

5.  The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers.

Authors:  D K Biswas; S C Dai; A Cruz; B Weiser; E Graner; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

6.  Possible contribution of aminopeptidase N (APN/CD13) to invasive potential enhanced by interleukin-6 and soluble interleukin-6 receptor in human osteosarcoma cell lines.

Authors:  A Kido; S Krueger; C Haeckel; A Roessner
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

7.  Activation and repression of interleukin-12 p40 transcription by erythroid Kruppel-like factor in macrophages.

Authors:  Qi Luo; Xiaojing Ma; Sharon M Wahl; James J Bieker; Merlin Crossley; Luis J Montaner
Journal:  J Biol Chem       Date:  2004-02-19       Impact factor: 5.157

8.  Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer.

Authors:  Suresh Kumar; Hiromitsu Kishimoto; Hui Lin Chua; Sunil Badve; Kathy D Miller; Robert M Bigsby; Harikrishna Nakshatri
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

9.  Whole Transcriptomic Analysis of Apigenin on TNFα Immuno-activated MDA-MB-231 Breast Cancer Cells.

Authors:  David Bauer; Elizabeth Mazzio; Karam F A Soliman
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

10.  Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10.

Authors:  Bridget Charbonneau; Matthew S Block; William R Bamlet; Robert A Vierkant; Kimberly R Kalli; Zachary Fogarty; David N Rider; Thomas A Sellers; Shelley S Tworoger; Elizabeth Poole; Harvey A Risch; Helga B Salvesen; Lambertus A Kiemeney; Laura Baglietto; Graham G Giles; Gianluca Severi; Britton Trabert; Nicolas Wentzensen; Georgia Chenevix-Trench; Alice S Whittemore; Weiva Sieh; Jenny Chang-Claude; Elisa V Bandera; Irene Orlow; Kathryn Terry; Marc T Goodman; Pamela J Thompson; Linda S Cook; Mary Anne Rossing; Roberta B Ness; Steven A Narod; Jolanta Kupryjanczyk; Karen Lu; Ralf Butzow; Thilo Dörk; Tanja Pejovic; Ian Campbell; Nhu D Le; Clareann H Bunker; Natalia Bogdanova; Ingo B Runnebaum; Diana Eccles; James Paul; Anna H Wu; Simon A Gayther; Estrid Hogdall; Florian Heitz; Stanley B Kaye; Beth Y Karlan; Hoda Anton-Culver; Jacek Gronwald; Claus K Hogdall; Diether Lambrechts; Peter A Fasching; Usha Menon; Joellen Schildkraut; Celeste Leigh Pearce; Douglas A Levine; Susanne Kruger Kjaer; Daniel Cramer; James M Flanagan; Catherine M Phelan; Robert Brown; Leon F A G Massuger; Honglin Song; Jennifer A Doherty; Camilla Krakstad; Dong Liang; Kunle Odunsi; Andrew Berchuck; Allan Jensen; Jan Lubinski; Heli Nevanlinna; Yukie T Bean; Galina Lurie; Argyrios Ziogas; Christine Walsh; Evelyn Despierre; Louise Brinton; Alexander Hein; Anja Rudolph; Agnieszka Dansonka-Mieszkowska; Sara H Olson; Philipp Harter; Jonathan Tyrer; Allison F Vitonis; Angela Brooks-Wilson; Katja K Aben; Malcolm C Pike; Susan J Ramus; Elisabeth Wik; Cezary Cybulski; Jie Lin; Lara Sucheston; Robert Edwards; Valerie McGuire; Jenny Lester; Andreas du Bois; Lene Lundvall; Shan Wang-Gohrke; Lukasz M Szafron; Sandrina Lambrechts; Hannah Yang; Matthias W Beckmann; Liisa M Pelttari; Anne M Van Altena; David van den Berg; Mari K Halle; Aleksandra Gentry-Maharaj; Ira Schwaab; Urmila Chandran; Janusz Menkiszak; Arif B Ekici; Lynne R Wilkens; Arto Leminen; Francesmary Modugno; Grace Friel; Joseph H Rothstein; Ignace Vergote; Montserrat Garcia-Closas; Michelle A T Hildebrandt; Piotr Sobiczewski; Linda E Kelemen; Paul D P Pharoah; Kirsten Moysich; Keith L Knutson; Julie M Cunningham; Brooke L Fridley; Ellen L Goode
Journal:  Cancer Res       Date:  2013-11-22       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.